"Robert Rosenson, MD: Treating Lower Extremity Arterial Disease in Diabetes" - Kevin Kunzmann
Researchers from the Icahn School of Medicine at Mount Sinai recently investigated adenosine enhancers on blood viscosity in patients with LEAD and type 2 diabetes. “In this trial, one of the major strengths is that every study participant received the same treatment. In other words, they received aspirin, ticagrelor, and aspirin-ticagrelor,” said study author Robert Rosenson, MD, professor of medicine, cardiology, and director of Cardiometabolic disorders at the Icahn School of Medicine at Mount Sinai. “Often in mechanistic studies, one would consider a limitation is imbalance in the group, but when you have everybody receiving all the therapies in random order, that's an important strength.”
— Robert Rosenson, MD, Professor, Medicine, Cardiology, Director, Cardiometabolic Disorders, Icahn School of Medicine at Mount Sinai